Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of recombinant human granulocyte macrophagocyte colony stimulating factor in preparation of drug for preventing and treating hepatitis B

A technology of colony stimulating factor and hepatitis B, applied in the field of medicine, can solve problems such as low response

Active Publication Date: 2007-07-04
华北制药金坦生物技术股份有限公司
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although aluminum adjuvant can enhance Th2 type immune response and humoral immunity, it can inhibit Th1 type immune response and cellular immunity, which may also be one of the factors that some people have low or no response to the existing hepatitis B vaccine ( Gupta R K, Siber G.R, Adjuvants for human vaccines-current status, problems and future prospects [J]. Vaccine, 1995, 13(14): 1263-1276.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of recombinant human granulocyte macrophagocyte colony stimulating factor in preparation of drug for preventing and treating hepatitis B
  • Use of recombinant human granulocyte macrophagocyte colony stimulating factor in preparation of drug for preventing and treating hepatitis B
  • Use of recombinant human granulocyte macrophagocyte colony stimulating factor in preparation of drug for preventing and treating hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] Experimental Example 1: Recombinant human granulocyte-macrophage colony-stimulating factor and genetically engineered hepatitis B vaccine synergistically induce cellular immune responses in mice Materials and instruments:

[0021] Experimental animals: BALB / C mice, SPF grade, female, weighing 16-18 g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.

[0022] Experimental materials: Genetic engineering (CHO cell) hepatitis B vaccine [Recombinant Hepatitis BVaccine (CHO)], 10μg / 1.0ml, recombinant human granulocyte macrophage colony-stimulating factor for injection [Recombinant Human Granulocyte / Macrophage Colony-Stimulating Factor for Injection ] (hereafter referred to as rhGm-csf), 300μg / support, the stock solution of genetically engineered hepatitis B vaccine (HBsAg stock solution) expressed by CHO is produced by North China Pharmaceutical Group Jintan Biotechnology Co., Ltd.

[0023] Main reagents and instruments: RPMI 1640 culture medium (...

experiment example 2

[0076] Experimental Example 2: Recombinant human granulocyte-macrophage colony-stimulating factor and genetically engineered hepatitis B vaccine synergistically induce humoral immune responses in mice

[0077] Materials and Instruments:

[0078] Experimental animals, materials, main reagents and instruments are the same as in Experimental Example 1.

[0079] Detection method:

[0080] 1. Serum antibody titer determination method:

[0081] Using the "Hepatitis B virus surface antibody ELISA diagnostic kit", the OD value of the sample / OD value of the negative control ≥ 2.1 is judged as positive (the OD value of the negative control is less than 0.05, calculated as 0.05), and the specific operation is shown in the instructions .

[0082] 2. Liver tissue section examination method (HE staining method):

[0083] After the mice were killed, cut the abdominal cavity with scissors, observe the liver tissue, cut off the middle lobe of the liver tissue, and immediately put it into nor...

experiment example 3

[0110] Experimental Example 3: Comparison of recombinant human granulocyte macrophage colony-stimulating factor and genetically engineered hepatitis B vaccine from three sources synergistically inducing cellular immune responses in mice

[0111] Materials and Instruments:

[0112] Experimental animals, main reagents and instruments are the same as in Experimental Example 1.

[0113] Experimental materials: Genetic engineering (CHO cell) hepatitis B vaccine [Recombinant Hepatitis BVaccine (CHO)], 10μg / 1.0ml, recombinant human granulocyte macrophage colony-stimulating factor for injection [Recombinant Human Granulocyte / Macrophage Colony-Stimulating Factor for Injection ] (hereinafter referred to as rhGm-csf), 300 μg / support, the genetically engineered hepatitis B vaccine stock solution (HBsAg stock solution) expressed by CHO is all produced by North China Pharmaceutical Group Jintan Biotechnology Co., Ltd.; recombinant (Hansenula) hepatitis B vaccine [Recombinant Hepatitis B Va...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a use of recombinant human granulocyte macrophage colony stimulating factor in the preparation of treatment or prevention hepatitis B, while includes simultaneous or successive given recombinant human granulocyte macrophage colony stimulating factor and genetic engineering hepatitis B vaccine for the prevention or treatment of hepatitis B.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the use of recombinant human granulocyte-macrophage colony-stimulating factor in preparing anti-hepatitis B drugs. Background technique [0002] Hepatitis B is a worldwide problem that endangers human health. According to the statistics of the World Health Organization, 400 million people in the world were infected with hepatitis B virus in 2000, and the hepatitis B virus infection rate in our country is as high as about 10%. Vaccination against hepatitis B is an important way to prevent and control the spread of hepatitis B. measure. [0003] Genetically engineered hepatitis B vaccine, including mammalian cell (such as: CHO cell) source and yeast source (such as: brewer's yeast cell), is a hepatitis B surface antigen (HBsAg) subunit vaccine, which adopts modern biotechnology The gene for expressing the surface antigen of the hepatitis B virus is constructed as a plasmid, cl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/29A61K38/19A61P1/16A61P31/14
Inventor 周兴军宋欣李立敏王惠欣董爱华王世聪贺建功谢德娟封华
Owner 华北制药金坦生物技术股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com